Details for New Drug Application (NDA): 203540
✉ Email this page to a colleague
The generic ingredient in RALTEGRAVIR POTASSIUM is raltegravir potassium. There are five drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the raltegravir potassium profile page.
Summary for 203540
Tradename: | RALTEGRAVIR POTASSIUM |
Applicant: | Hetero Labs Ltd Iii |
Ingredient: | raltegravir potassium |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 203540
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 400MG BASE | ||||
Approval Date: | Dec 19, 2024 | TE: | RLD: | No |
Complete Access Available with Subscription